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ABSTRACT The broad range and diversity of interferon-stimulated genes (ISGs) function to induce an antiviral state within the
host, impeding viral pathogenesis. While successful respiratory viruses overcome individual ISG effectors, analysis of the global
ISG response and subsequent viral antagonism has yet to be examined. Employing models of the human airway, transcriptomics
and proteomics datasets were used to compare ISG response patterns following highly pathogenic H5N1 avian influenza (HPAI)
A virus, 2009 pandemic H1N1, severe acute respiratory syndrome coronavirus (SARS-CoV), andMiddle East respiratory syn-
drome CoV (MERS-CoV) infection. The results illustrated distinct approaches utilized by each virus to antagonize the global ISG
response. In addition, the data revealed that highly virulent HPAI virus andMERS-CoV induce repressive histone modifications,
which downregulate expression of ISG subsets. Notably, influenza A virus NS1 appears to play a central role in this histone-
mediated downregulation in highly pathogenic influenza strains. Together, the work demonstrates the existence of unique and
common viral strategies for controlling the global ISG response and provides a novel avenue for viral antagonism via altered
histone modifications.
IMPORTANCE This work combines systems biology and experimental validation to identify and confirm strategies used by viruses
to control the immune response. Using a novel screening approach, specific comparison between highly pathogenic influenza
viruses and coronaviruses revealed similarities and differences in strategies to control the interferon and innate immune re-
sponse. These findings were subsequently confirmed and explored, revealing both a common pathway of antagonism via type I
interferon (IFN) delay as well as a novel avenue for control by altered histone modification. Together, the data highlight how
comparative systems biology analysis can be combined with experimental validation to derive novel insights into viral pathogen-
esis.
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Acute respiratory tract infections represent a considerablethreat, causing significant morbidity and mortality globally
(1). In particular, emerging pathogens, including influenza A vi-
rus and coronavirus, have caused minor to major outbreaks of
viral pneumonia worldwide (2). In the current work, we com-
pared the host response to four distinct emerging respiratory vi-
ruses: a highly pathogenic H5N1 avian influenza (HPAI) virus,
influenza A/Vietnam/1203/2004 (H5N1; referred to as H5N1-
VN1203); a 2009 pandemic influenza virus, A/California/04/2009
(H1N1; referred to as H1N1-09); severe acute respiratory syn-
drome coronavirus (SARS-CoV); and the recently emergentMid-
dle East respiratory syndrome CoV (MERS-CoV). Each viral fam-
ily causes severe disease, encodes several immune-modulatory
elements, and remains a threat for future pandemics (2, 3). How-
ever, despite similar disease manifestations, influenza viruses and
CoVs also exhibit sharp contrasts in terms of replication, immune
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stimulation, and overall lethality (4). Together, the similarities
and differences offer an opportunity to identify both conserved
and pathogen-specific host responses important during respira-
tory virus infection.
While previous studies have undertaken global analysis built
on systems biology datasets (5–8), we took a new approach that
focused on a parameter known to be important to viral infection:
the interferon (IFN)-stimulated gene (ISG) response. Type I IFN
induces a signaling cascade that provides the first line of defense
against viral pathogens and initiates transcription of hundreds of
ISGs that have antiviral, immune modulatory, and cell regulatory
functions (9). Successful viral pathogens, including CoVs and in-
fluenza viruses, have evolved genetic functions that antagonize
pathogen recognition as well as ISG effector functions (10, 11).
Yet, as awhole, the ISG response has never been globally examined
in the context of multiple viral pathogens in the same system;
therefore, we sought to compare and contrast ISG control strate-
gies employed by influenza A and pathogenic CoVs.
Using virologic and transcriptomic data, the results demon-
strated distinct approaches used by each virus to interfere with the
global ISG response. Differences and similarities were noted be-
tween strains within each virus family, and expression patterns
were further validated by proteomic data. Finally, computational
and empirical studies provided insights into conserved and novel
mechanisms of ISG control. Whereas the HPAI virus actively ma-
nipulated the ISG response with up- and downregulation of ISG
subsets, H1N1-09 produced strong, uniform induction. In con-
trast, SARS-CoVandMERS-CoV successfully delayed ISG expres-
sion until after peak viral titers were achieved. Notably, MERS-
CoV also downregulated a subset of ISGs, overlapping part of the
signature seen with HPAI virus. Mechanistic studies revealed that
absent and delayed IFN induction was responsible for the ISG
antagonism observed in the CoVs. In addition, ISG downregula-
tion in both HPAI virus and MERS-CoV was not due to disrup-
tion of signaling but rather correlates with altered histone modi-
fication, a novel avenue to impede ISG transcription. Finally,
varied antagonism of HPAI virus mutants suggested that NS1
contributes to ISG control via altered histone methylation and
may impact virulence in other severe influenza virus infections.
Together, the data highlight unique and conserved approaches
used by disparate respiratory viral pathogens to manipulate and
control the global ISG responses.
RESULTS
Type I IFN treatment and viral infections induce diverse ISG
expression profiles. ISG expression varies based on cell and tissue
type. Therefore, we set out to define ISGs in Calu3 cells, a human
respiratory cell line permissive for both CoV and influenza infec-
tion. Calu3 cells were treated with type I IFN (IFN- or IFN-),
resulting in differential expression of 350 genes (log2 fold
change [FC] of 1.5, adjusted P value of 0.05; Fig. 1A). Using
these data, a consensus ISG list was developed from genes induced
at more than one time point (see Table S1 in the supplemental
material) and then used to examine ISG expression changes fol-
lowing infection. While cytopathic effect (CPE) in both H5N1-
VN1203 and H1N1-09 required a slightly lower multiplicity of
infection (MOI) to maximize comparable time points, infection
of the cultures was uniform (95% infection), as measured by
CPE or fluorescent virus infection. In addition, each infection
maintained similar kinetics in terms of both replication and
genomic RNA production despite differing endpoint titers (Fig.
1B and C).
Following IFN- treatment or infection, the ISG RNA expres-
sion patterns showed both similarities and stark contrasts
(Fig. 1D). H1N1-09 quickly and robustly induced the majority
(97%) of ISGs,mimicking type I IFN treatment. However, H5N1-
VN1203 induced robust induction in only 35% of the consensus-
annotated ISGs (log2 FC of 0.75 at 24 h postinfection [hpi])
(Fig. 1D, orange panel); in contrast, a significant subset of ISGs
(26%) had only minimal induction (green panel). Finally, the
largest percentage (39%; log2 FC of0.75 at 24 hpi, purple and
blue panels) was downregulated relative to mock following
H5N1-VN1203 infection. Based on these groupings, the same
ISGs were almost uniformly upregulated in response to H1N1-09
infection (Fig. 1D). In contrast, ISG expression was neither
strongly up- nor downregulated following the first 12 h of SARS-
CoV infection; only after 24 to 36 hpi are the majority (88% at
72 hpi) of ISGs induced. However, several ISGs showed onlymin-
imal, if any, stimulation (e.g., TLR3, SERPIN1), and ACE2, the
receptor for SARS-CoV, was downregulated, corresponding with
previous reports (12). ForMERS-CoV, the first 12 h also found no
significant ISG induction, afterwhich expressionmirroredH5N1-
VN1203 with upregulation (42%), no stimulation (39%), and
downregulation (19%) of ISG subsets (see Table S1). Together,
these results demonstrate contrasting and overlapping ap-
proaches used by H5N1-VN1203, H1N1-09, SARS-CoV, and
MERS-CoV in their regulation of the global ISG response.
Proteomic analysis validated ISGantagonism followingCoV
and influenza virus infection. In parallel to RNA expression ex-
periments, infectedCalu3 cells were examined by global proteom-
ics analysis. Numerous factors affect proteomics coverage, includ-
ing a protein’s solubility, hydrophobicity, and location within the
cell, thus preventing analysis of major protein subsets, including
secreted and membrane-bound peptides. Despite these limita-
tions, significant changes in protein levels provided independent
validation of the RNA expression trends. For H1N1-09, the lim-
ited control of ISG RNA expression also manifested in robust ISG
protein production; 27 ISG proteins were among 530 significantly
upregulated host proteins (P or G test value of0.05 at any time
point; see Fig. S1A in the supplementalmaterial), with production
detected as early as 12 hpi and the majority of ISG protein (63%)
produced by 24 hpi. In contrast, only 3 of the 382 proteins signif-
icantly upregulated by H5N1-VN1203 belonged to the consensus
ISG list, validating the RNA expression analysis.While SARS-CoV
induces 20 ISG proteins over its 72-h time course, none of these
ISG proteins are detected prior to 30 hpi; similarly, MERS-CoV
induces five ISGproteins, with only one (STAT1) detected prior to
18 hpi, thus confirming delayed ISG induction in both CoVs.
Examination of individual protein expression patterns also
confirmed these trends. Although most ISGs are absent in mock
samples, two detectable proteins were expressed at basal levels:
STAT1 and PKR. H5N1-VN1203 infection had reduced protein
expression of both STAT1 (27.4% decrease at 24 hpi) and PKR
(28.5% decrease at 18 hpi) relative to that of mock; similarly,
MERS-CoV reduced the protein level of STAT1 (15.8% decrease
at 18 to 24 hpi) and PKR (20.2% decrease at 18 to 24 hpi) (see
Fig. S1B). In contrast, both proteins were significantly increased
following both H1N1-09 and SARS-CoV infection; however, the
increase occurred only at late times (30 hpi) for SARS-CoV,
contrasting that for H1N1-09. Further examination of individual
Menachery et al.
2 ® mbio.asm.org May/June 2014 Volume 5 Issue 3 e01174-14
ISGs found a consistent linkage between mRNA expression (see
Fig. S1B, solid line) and protein abundance (dotted line). For
H1N1-09, mRNA upregulation by 3 to 7 hpi corresponded to
parallel protein production 7 to 12 h later for ISGs; representative
kinetics forMX1, OAS2, and IFIT family members are shown (see
Fig. S1C). A similar mRNA/protein kinetic relationship was ob-
served for SARS-CoV, showing delayed RNA induction, which
allowed viral replication to peak prior to ISG protein production
(see Fig. S1D). For both H5N1-VN1203 and MERS-CoV, this
analysis was excluded due to insufficient detectable data to pro-
duce a representative curve. Together, the proteomics data vali-
dated the RNA expression results and confirmed unique strategies
to control the ISG response between different viral strains and
families.
Delayed IFN induction mediates ISG antagonism by CoVs.
Having established differential ISG regulation at both the RNA
and protein levels, we next sought to determine the means of
control. One possible global mechanism is to prevent, disrupt, or
delay initial induction of either type I or type III IFN, another
important antiviral cytokine. While several IFN-independent
ISGs exist, the vast majority of genes are augmented by IFN pro-
duction (9); naturally, both CoV and influenza family members
have developed approaches to prevent this induction by disturb-
ing the sensing pathways (10, 11). Yet, despite the presence of
antagonists, bothH5N1-VN1203 andH1N1-09 infection resulted
in robust transcription of type I and type III IFN molecules
(Fig. 2A); IFN-1, IFN-5, and IFN-1 were each strongly in-
duced in both influenza strains. These results are consistent with
FIG 1 Type I IFN treatment and viral infections induce diverse ISG expression profiles. (A) Total number of genes induced by type I IFN treatment with a log2
FC of1.5 at indicated time points in Calu3 cells. Red numbers indicate genes included in the consensus ISG list (see Table S1 in the supplemental material). All
ISG and analysis available online as outlined in data dissemination (supplement). Viral titers (B) and viral genomic RNA (C) following infection of Calu3 cells
with H5N1-VN1203 (MOI of 1; blue), H1N1-09 (MOI of 3; red), SARS-CoV (MOI of 5; green), or MERS-CoV (MOI of 5; orange). (D) Global ISG transcrip-
tional response to IFN- treatment or infection. Genes ordered byMERS-CoVorH5N1-VN1203 expression levels 24 hpi and grouped into subsets based on fold
change: downregulated in both MERS-CoV and H5N1-VN1203 (purple; 0.75), downregulated in H5N1-VN1203 (blue; 0.75), minimal stimulation
(green; 0.75 to0.75), and upregulated (orange;0.75). Values represent log2 FC compared to time-matched mocks.
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previous reports for both viruses (13, 14) and indicated host rec-
ognition via intact sensing pathways despite the presence of IFN
antagonists like NS1. In contrast, SARS-CoV infection resulted in
IFN- induction only after 12 h (Fig. 2); IFN-5 and IFN-1were
even further delayed and dampened compared to those in the
influenza infections. Similarly, MERS-CoV failed to induce IFN
genes prior to 12 h but also induced more robust IFN-5 relative
to that of SARS-CoV, possibly implicating signaling differences in
antagonism between the two CoVs. Together, the IFN induction
data indicated that unlike the influenza strains, CoV infections
more tightly block recognition and/or disrupt IFN induction.
Coupled with previous reports of the sensitivity of SARS- and
MERS-CoV to type I IFN (15, 16), these data argued that delayed
ISG expression enhances CoV infection.
Transcriptional factor binding preference corresponds with
differential ISG expression. For H1N1-09 infection, robust IFN
expression syncs with observed global ISG induction (Fig. 1D). In
contrast, while the strong induction of type I and III IFN corre-
sponds to previous reports for H5N1-VN1203 (14), the up- and
downregulation of ISG subsets indicate that the global IFN re-
sponse is altered by the more virulent influenza strain. Notably,
while blocking recognition pathways and IFN signaling have been
described as means to impair ISG induction (10, 17), neither ap-
proach would directly result in ISG downregulation relative to
mock. In fact, the results suggest that H5N1-VN1203 ISG antag-
onism occurs after pathway activation, possibly through interfer-
ing with transcriptional factor binding. However, ingenuity path-
way analysis (IPA) of IRF7-, STAT1-, and NF-B-dependent
genes demonstrated no uniform pattern of either specific induc-
tion or repression 12 h afterH5N1-VN1203 infection (see Fig. S2A
in the supplemental material; also, data not shown); in addition,
IPA upstream Z scoring, a value based on downstream expression
of connected genes, revealed lower activation scores for these tran-
scriptional factors in H5N1-VN1203 than in H1N1-09 but no
evidence of repression (Z score2.0), reflecting both increased
and decreased downstream ISG expression (see Fig. S2B to D).
The analysis suggested that H5N1-VN1203 does not achieve
downregulation via blockade of transcriptional factors; instead,
these data and IFN expression values indicate that upstream ISG
signaling remains intact.
While unable to completely block activation, H5N1-VN1203
may dampen the total amount of activated transcriptional factor
via antagonists like NS1. With limited availability, transcriptional
factor binding preference may drive differential expression. To
explore this possibility, we focused on STAT1-dependent/aug-
mented ISGs as determined by the IPA knowledge base; the results
identified broad variation in ISG expression despite their similar
dependence on STAT1 (Fig. 3A). To verify that transcriptional
factor binding contributed to this observation, we performed
chromatin immunoprecipitations (ChIP) targeting STAT1, fol-
lowed by quantitative real-time PCR (qPCR) to examine target
promoter binding. The results indicated that CXCL10 and IFIT1,
highly expressed ISGs following H5N1-VN1203 infection
(Fig. 3A), had a corresponding increase in STAT1 binding in their
5= promoter region at 12 hpi (Fig. 3B). In contrast, CFHR1 and
APOL6, ISGs with decreased expression, had no increase in
STAT1 binding despite the presence of activated STAT1 in those
cells. For each of these genes, we had identified consensus STAT1
GAS motifs (TTC[N 2–4]GAA) within 1 kb of the translational
start site and 200 bp downstream (18); the number of thesemotifs
varied by gene (CXCL10 [2], IFIT1 [1], CFHR1 [1], APOL6 [1])
but did not dictate expression of STAT1. Notably, similar varia-
tion despite STAT1 dependence was observed following MERS-
CoV infection as well as with STAT1ChIP-PCR results (see Fig. S3
in the supplemental material). Together, the results indicated that
differential promoter binding exists between genes activated by
STAT1 and possibly contributes to differential ISG expression in
H5N1-VN1203 and MERS-CoV infections.
FIG 2 Delayed IFN induction mediates ISG antagonism by CoVs. Individual
gene RNA expression of IFNB1, IFNL1, and IFNA5 molecules derived from
microarray following H5N1-VN1203 (blue), H1N1-09 (red), SARS-CoV
(green), or MERS-CoV (orange) infection.
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Altered histone modification plays a significant role in both
H5N1 andMERS-CoV ISG antagonism.Anumber of factors can
impact transcriptional factor binding preference, including the
promoter binding sequence, site of phosphorylation, and under-
lying chromatin structure (19, 20). We initially chose to focus on
chromatin structure based on a number of studies that implicated
a role for chromatin remodeling during influenza virus infection
(21–23) and identification of histone mimic (24). Histone modi-
fication can mediate a variety of diverse biological processes, in-
cluding gene regulation (25, 26). These changes can result in rapid
chromatin remodeling, including activation (opening) or repres-
sion (closing) depending on the location, type, and number of
modifications. While the NS1 histone mimic motif is absent in
both H1N1-09 and H5N1-VN1203, other findings suggest that
histone remodeling strategies may be conserved across influenza
strains (21–23). Coupled with substantial downregulation of ISG
subsets during H5N1 infection, these facts encouraged us to in-
vestigate histone changes. We performed ChIP using antibodies
for either an active form of histoneH3 (H3K4me3) or a repressive
form (H3K27me3) in the context of H5N1-VN1203 or H1N1-09
infection (25).We then targeted the 5= untranslated region (UTR)
of three ISGs with differential expression between the influenza
strains (CFHR1,DDX58 [encodes RIG-I], and SMAD9L) and one
with similar expression (IRF9) by quantitative real-time PCR. For
H1N1-09, H3K4me3 was strongly associated with the 5=UTR of
upregulated ISGs compared to mock (Fig. 4A). In contrast, these
same genes, with downregulated RNA expression in H5N1-
VN1203 infection, were also found to have significantly reduced
association with H3K4me3, suggesting the absence of the active
H3 motif. Examining the repressive H3K27me3 revealed en-
hanced association with CFHR1, DDX58, and SMAD9L during
H5N1-VN1203 infection (Fig. 4B); no significant H3K27me3 as-
sociation was observed for these genes following H1N1-09 infec-
tion. IRF9, an ISG upregulated following both H1N1-09 and
H5N1-VN1203 infection, demonstrated similar trends for both
H3K4me3 and H3K27me3, with no significant differences ob-
served between the strains (Fig. 4A and B). Together, the results
indicate that altered histone modification occurs in the context of
H5N1-VN1203 infection and these patterns of change correlate
with the observed differences in ISG antagonism.
Having demonstrated significant differences in histone modi-
fication patterns that correlate with expression outcomes between
FIG 3 STAT1 binding corresponds with differential ISG expression. (A) RNA
expression of consensus ISGs linked to STAT1 following H5N1-VN1203 in-
fection. Values represent log2 FC relative to time-matched mocks. (B) Chro-
matin immunoprecipitation with antibodies against phospho-STAT1 (Santa
Cruz) followed by qPCRof the 5=UTRof upregulated genesCXCL10 and IFIT1
or downregulated genes CFHR1 and APOL6 in the context of H5N1-VN1203
infection.Values represent fold increase binding compared tomock on a linear
scale.
FIG 4 Altered histonemodifications play a significant role in both H5N1 and
MERS-CoV ISG antagonism. Chromatin immunoprecipitation with antibod-
ies against H3K4me3 (A and C) or H3K27me3 (B and D) followed by qPCR of
the 5=UTR of the identified genes 12 h postinfection with H1N1-09 (red),
H5N1-VN1203 (blue), SARS-CoV (green), or MERS-CoV (orange). Values
represent fold increase binding compared to mock on a log2 scale. P values
based on Student’s t test and are marked as indicated: *,0.05; **,0.01; ***,
0.001.
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influenza strains, we returned to the CoVs. While both
MERS-CoV and SARS-CoV maintain delayed IFN in-
duction (Fig. 2), MERS-CoV also downregulated a sub-
set of ISGs with kinetics similar to those of H5N1-
VN1203 (Fig. 1D); no similar subset was observed during
SARS-CoV infection. Given its increased sensitivity to
type I IFN (15, 16), one possibility is that MERS-CoV
employed an additional layer of ISG antagonism via al-
tered histone modification. To test this idea, ChIP-PCR
was again employed following both MERS-CoV and
SARS-CoV infection. The results demonstrated that two
genes (TLR3 andCFHR1) downregulated in bothH5N1-
VN1203 and MERS-CoV, but not SARS-CoV infection,
had decreased association with activating H3K4me3
(Fig. 4C) and increased association with the repressive
H3K27me3 motif (Fig. 4D). In contrast, DDX58, a gene
downregulated by H5N1-VN1203 but not MERS-CoV,
actually had reduced H3K27me3 association following
MERS-CoV infection. Similar to previous reports (27),
the activating histone mark was variable in uninduced
SARS-CoV-infected samples at 12 hpi; however, a late
time point (36 hpi) that corresponded with robust ISG
expression demonstrated increased H3K4me3 and re-
duced H3K27me3 modifications relative to mock (see
Fig. S4 in the supplemental material). Together, the data
suggested that while the activatingmotif was less predict-
able, the dominant H3K27me3 repressive histone mark
was associated only with ISGs downregulated by both
MERS-CoV and H5N1-VN1203 (28).
NS1 mediates ISG manipulation in virulent influ-
enza virus strains. To explore how H5N1-VN1203 me-
diates ISG control, we next focused on viral proteins
linked to H5N1-VN1203 virulence and IFN manipula-
tion: NS1, PB1-F2, and PB2 (29–32). To test the contri-
butions of these viral proteins, Calu3 cells were infected
with H5N1-VN1203 mutants containing a C-terminal
truncation of NS1 (NS1trunc124), a deletion of PB1-F2
(PB1-F2del), or PB2 encoding an amino acid substitu-
tion (PB2-K627E) that significantly reduces polymerase
activity. For each, viral replication and ISG induction
was compared to those of the wild type (WT) and dem-
onstrated attenuated replication, noting that each mu-
tant virus replicated to equivalent titers at 18 to 24 h (see
Fig. S5A in the supplemental material). However, ISG
induction kinetics varied between both theWT virus and
each mutant (Fig. 5A). For the PB1-F2del and PB2-
K627E mutants, a significant subset of ISGs (48.5% for
PB1-F2del and 38.8% for PB2-K627E; data not shown)
FIG 5 H5N1-VN1203 mediates control over the global ISG re-
sponse primarily through the activity of NS1. (A) RNA expression
of downregulated ISGs following each infection condition. Down-
regulated gene list was derived fromFig. 1C, and values represent
fold change (log2 FC) compared to time-matched mocks. (B and
C) ChIP against H3K4me3 (B) and H3K27me3 (C) followed by
qPCR of the 5=UTR of the identified genes within the context of
H5N1-VN1203 (blue) or H5N1 NS1trunc124 (white) infection.
Values represent fold increases in binding compared to mock on a
log2 scale. (D) Global transcription of consensus ISG from A549
cells infected with WT 1918 H1N1 or 1918 H1N1 encoding TX/91
NS1 (MOIof 2). RNAexpression values represent fold change (log2
FC) compared to time-matched mock.
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had augmented expression (1.5 log2 FC) compared to theWT at
24 hpi; however, 95% of genes downregulated in WT infections
also remained downregulated (24%,0.75 log2 FC expression)
or uninduced (74%, 1.5 log2 FC expression) by both of these
mutants. In contrast, compared to WT H5N1-VN1203, the
NS1trunc124 mutant induced a larger subset and augmented ex-
pression (71%) of ISGs (1.5 log2 FC) (data not shown). Impor-
tantly, of the 41 consensus ISGs downregulated during H5N1 in-
fection, 38 were no longer downregulated and over half (51%)
were upregulated (1.5 log2 FC expression) following infection
with the mutant NS1 virus. Proteomics analysis validated these
results, demonstrating increased protein expression of 11 ISGs in
H5N1-NS1trunc124 infection, including MDA5, MX1, and
IFIT1, which were not detectable in WT infection (see Fig. S3B).
Together, these results suggest that the NS1 C terminus plays a
role in selective ISG downregulation and makes a strong contri-
bution to global ISG control following H5N1-VN1203 infection.
Having established NS1 as a required component for strong
ISG manipulation and downregulation, we next sought to deter-
mine if histone modifications of specific ISGs were modified in
H5N1-NS1trunc124 infections. For this, we repeated the ChIP-
PCR experiment with WT and NS1trunc124 viruses (Fig. 5B and
C). Similar to what was previously observed, ISGs that were tran-
scriptionally downregulated in WT infections (i.e., SMAD9L,
CFHR1, and DDX58) were strongly associated with repressed hi-
stones (H3K27me3) and only weakly associated with active his-
tones (H3K4me3). In contrast, the absence of full-length NS1 re-
sulted in augmented association of the same transcripts with the
active H3K4me3 and reduced binding to the inhibitory
H3K27me3 mark. Together, the data demonstrated that histone
modifications were altered in the absence of full-length NS1 and
may result in the augmented ISG RNA and protein expression
following NS1trunc124 mutant virus infection.
We next sought to determine if NS1 from another highly
pathogenic virus mediated a similar global ISG response. With
this inmind, ameta-analysis was conducted onmRNA expression
data from A549 cells infected with pandemic 1918 H1N1 and a
1918 H1N1 mutant expressing NS1 from a seasonal H1N1 strain
(A/Texas/36/91 [TX]) (33). Each of these viruses maintained a
full-length NS1 but lacked the histone mimic motif found in
H3N2. Confirming the original findings, several ISGs had a sub-
stantial increase in expression after infection with recombinant
virus encoding the TX NS1 compared to the WT 1918 NS1
(Fig. 5D). However, expanding the examination to the consensus
ISG list derived from Calu3 cells to the A549 cell metadata re-
vealed that expression of ISGs was not uniformly downregulated
with 1918 NS1. Instead, many ISGs had equivalent expression
levels, and several (IFITM1, ZBP1, HSH2D, etc.) had greater ex-
pression with 1918 NS1 than TX NS1. These results suggest that
NS1 substitution from a more virulent strain does not always re-
sult in uniform ISG augmentation but rather targets ISG manip-
ulation based on strain specific NS1 activity. Notably, ISG down-
regulation was absent in the less virulent TX NS1 (0 genes)
compared to in the 1918 NS1 (21% 0.25 log2 FC at 24 hpi);
coupled with data from H5N1-VN1203 and MERS-CoV infec-
tions, these results suggest that pathogenic respiratory virusesmay
downregulate a subset of ISGs via histone modification and con-
tribute to effective infection and enhanced virulence.
DISCUSSION
This study demonstrates contrasting, similar, and novel avenues
used by virulent respiratory viruses to dampen and impair the
global ISG response. HPAI utilizes rapid manipulation resulting
in both strong up- and downregulation of ISG subsets rather than
a binary ISG response. In contrast, the less virulentH1N1-09 virus
fails to modulate either ISG transcripts or protein, producing a
robust antiviral state which may impact peak titers. Similarly,
SARS-CoV infection stimulates robust ISG transcription and pro-
tein production; however, ISGs are delayed 24 to 48 h, permitting
SARS-CoV to achieve peak titers prior to ISG production. Finally,
MERS-CoV not only delays ISG induction but also manipulates a
subset of ISGs, similar toH5N1-VN1203. Together, the data high-
light methods that pathogenic viruses utilize to control the host
antiviral state. In each case, the strategy contributes to successful
infection and may explain differences in virulence seen between
viral families and strains.
In addition to identifying differential ISG induction profiles,
this study also introduces a novel avenue for viral antagonism of
host gene expression via altered histone modification (Fig. 6). A
large number of host enzymes catalyze methylation and demeth-
ylation of histones, a process that is essential for regulating tran-
scriptional programs (26, 34). In particular, innate immune re-
sponses, including ISG responses, are highly regulated by
epigenetic control mechanisms, including alteration of methyl-
ation and acylation patterns in chromatin (35, 36). By catalyzing
the placement or removal of histonemethyl marks at H3K4 (tran-
scriptionally active) and H3K27 (transcriptionally repressive), hi-
stone lysine methyltransferases (MLL2, MLL3, and EZH2) and
demethylases (RBP2, UTX, and JMJD3) modify the chromatin
state to maintain and fine-tune transcriptional control (26). Dur-
ing H1N1-09 or SARS-CoV infection, the host cell recognizes the
viruses, produces type I and type III IFN, and induces histone
modulation complexes to remove the repressive histone marks
(H3K27me3) and add activating modifications (H3K4me3); this
FIG 6 Model of histone modification changes during highly virulent respi-
ratory virus infection. Viral infection induces changes in the basal state of host
chromatin. For H1N1-09 and SARS-CoV, infection results in H3K4me3 in-
corporation (green ovals), reduced H3K27 (red diamonds), and an open con-
firmation. In contrast, for H5N1-VN1203 and MERS-CoV, infection aug-
ments H3K27me3 incorporation and reduces H3K4me3 for a subset of genes,
resulting in a closed conformation that excludes activated transcription factors
and represses ISG expression.
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process shifts targeted chromosomal locations to a more open,
activated state and permits the binding of activated transcription
factors like STAT1 and IRF7, allowing robust ISG expression. In
contrast, during MERS-CoV and H5N1-VN1203 infection, some
histones undergo the activating modifications resulting in robust
expression of a subset of ISGs; however, for another subset of
genes, chromatin remodeling complexes incorporate the repres-
sive histone modification (H3K27me3) while also removing the
active marker (H3K4me3), resulting in a condensed chromatin
structure. This closed structure likely excludes transcription fac-
tors and reduces RNA expression of target ISGs.While differences
in transcriptional factor phosphorylation state or binding sites
may also contribute, the altered histone modification approach
suppresses expression of target genes. While histone modification
has been shown to play a role in a variety of host processes, includ-
ing cell development (37), host metabolism (38), and ISG induc-
tion (36), these findings represent additional evidence that patho-
gens can exploit the same repression processes to modulate and
control the host IFN response (39, 40); similar modulation by
pathogens likely impacts other critical host processes, including
inflammation, antigen presentation, and aging (26, 34). The pres-
ence of this antagonism in disparate, highly virulent respiratory
pathogens not only supports earlier studies involving the H3N2
NS1 histone mimic (24) but also suggests that the approach may
be conserved across multiple viral families and contribute to en-
hanced disease virulence. The large number of cellular proteins
present within histone modification complexes potentially pro-
vides a rich diversity of targets for pathogen-coded control and
manipulation (26). Importantly, antagonizing histone regulation
may also prove to be an important factor in the emergence of both
H5N1-VN1203 and MERS-CoV; broad evolutionary conserva-
tion of both histone modifications and machinery suggests that
host targets may be conserved across diverse species, potentially
easing cross-species infection by modulation of the host response
(41). However, the effect may also be reducing transmission effi-
ciency by removing portions of the adaption requirements for
host shifting. Future studies explore avian- and bat-derived cells
for conservation of virus-mediated histone modification.
For influenza viruses, ISG expression differences between
H5N1-VN1203 and H1N1-09 highlighted possible virulence de-
terminants. Numerous reports have shown that specific influenza
proteins impede the type I IFN response by targeting host signal-
ingmolecules and transcription factors (9, 10); together, the stud-
ies imply that disruption of these components results in a loss or
dampening of the entire pathway’s downstream components.
However, robust IFN production followingH5N1-VN1203 infec-
tion confounds this interpretation (21–23); instead, these data
argue that during H5N1-VN1203 infection, host recognition and
IFN signaling remain largely intact and a hierarchy in ISG activa-
tion exists. In contrast, the less virulent H1N1-09 virus lacks sim-
ilar ISG antagonism both at the RNA and protein levels. Several
HPAI viral protein functions may have contributed to ISG down-
regulation prior to mRNA production, including cap snatching,
cleavage and polyadenylation specificity factor (CPSF) interfer-
ence, and/or microRNA targeting (42–44). However, each possi-
bility would lead to nonspecific degradation of mRNA and thus
could not explain the differential ISG expression observed in these
studies. In contrast, significant changes in histone activation and
repression marks, coupled with interaction with histone compo-
nents (21–23) and the recent discovery of a histone mimic in
H3N2 infection (17, 24), provided a rational avenue for the ob-
served contrast in ISG antagonism.
Mechanistically, C-terminal truncation of NS1 ablated global
ISG antagonism for H5N1-VN1203. While mutations in PB1-F2
and PB2 resulted in significant ISG augmentation, the majority of
ISGsmaintain low or downregulated expression. In contrast, NS1
truncation halted ISG downregulation by H5N1-VN1203 and en-
hanced expression of a significant subset of ISGs at both the RNA
and protein levels. This ISG stimulation occurred despite the pres-
ence of both the RNA-binding domain and part of the effector
domain for NS1 (45). Infection with the NS1 truncation mutant
also resulted in reduced association with the repressive
H3K27me3 and increased association with the active H3K4me3,
identifying a role for NS1 in altered histone modification. To-
gether, the data indicate a role for NS1 beyond just IFN pathway
inhibition and identifies histone modification as a new target for
ISG antagonism in H5N1-VN1203 infection.
While NS1 histone mimicry has been identified in an H3N2
virus, the responsible binding motif is not contained in either
H5N1-VN1203 or 1918 H1N1 (24). This suggests that the
C-terminal portion of NS1 may mediate selective ISG subset
downregulations through different mechanisms depending on
strain. For H5N1-VN1203, NS1 may target a similar functional
pathway as H3N2 by mimicking different histones, targeting
histone-modifying enzymes, or disrupting a histone adaptor pro-
tein complex. For H1N1-09, it suggests that the absent 11-amino-
acid C-terminal truncation of NS1 may contribute to its relative
lack of ISG antagonism; this absent tail has multiple functional
domains in addition to possible histone modification elements
(17, 46, 47). Together, these possibilities illustrate the complexity
of NS1 and the caveats of analyzing its contribution to histone
modification; however, further study with the plethora of H5N1-
VN1203 and H1N1-09 viral mutants provides a golden opportu-
nity to further characterize NS1’s role in ISG manipulation.
The data also lent the possibility that NS1 from other patho-
genic influenza strainsmaymediate differential antagonism of the
ISG subset in addition to interfering with host recognition. Meta-
analysis of NS1 from 1918 H1N1 and a seasonal influenza virus
supports this possibility; while derived from Calu3 cells, the ex-
panded ISG list demonstrated that control was altered between
virulent and avirulent strains based onNS1, and the data indicated
that the directions of expression changes were not uniformly in
favor of the more virulent strain. Variant responses in viruses
encoding different NS1 genes imply the existence of categories of
NS1 genes that may target different aspects of the host immune
response. This fact, coupled with highly species-specific virulence
determinants (48, 49), suggests that NS1 genes may circulate and
contribute to species-specific severe disease outcomes, perhaps by
coordinating unique patterns of histone modification that regu-
late the ISG in addition to standard IFN pathway antagonism.
Importantly, exploring the global mechanism of ISG manipula-
tion by NS1 genes within the context of infection, in addition to
transfection-based approaches, will provide significant insights
into disease severity across different hosts, tissues, and species.
The data also highlight the ability of both SARS-CoV and
MERS-CoV to inhibit recognition, delay IFN induction, and se-
quester ISG production until after peak viral titers had been
achieved. This ability effectively neutralizes the innate immune
response and permits both CoVs to establish a foothold within the
lung prior to recognition. However, MERS-CoV and SARS-CoV
Menachery et al.
8 ® mbio.asm.org May/June 2014 Volume 5 Issue 3 e01174-14
also utilize additional divergent approaches to limit the host IFN
response. While SARS-CoV IFN antagonism is well established
(11),MERS-CoV appears to employ different, less effective antag-
onists, resulting in increased sensitivity to type I IFN pretreatment
(15, 16). However, altered histonemodification represents a novel
CoV antagonism approach. While newly emergent, several
MERS-CoV proteins have been identified as IFN antagonists (50,
51); notably, ORF4b, a MERS accessory protein with no homo-
logue in SARS-CoV, maintains a purported nuclear localization
signal, exhibits nuclear localization based on transfection, and
may play a role in IFN antagonism (51). Further studies are under
way utilizing theMERS-CoV infectious clone (52) and attempt to
identify viral components required to mediate altered histone
modification.
Overall, this study combines a systems biology approach that
integrates complex RNA and proteomics datasets across different
virus infections with detailed molecular and cell biology valida-
tion approaches to identify novel patterns and mechanisms of
virus-host interaction and innate immune regulation.While ISGs
have been previously known to be an important factor during viral
infection, global analysis has been limited by the lack of uniform
platforms, infection conditions, and data collection methods. Es-
tablishing conditions that afford comparisons across systems vi-
rology datasets alleviated these problems and permitted analysis
beyond a single treatment or infection condition. The resulting
study revealed similarities and stark contrasts in terms of ISG in-
duction between SARS-CoV, MERS-CoV, an HPAI virus, and a
2009 pandemic influenza virus strain, which likely contribute to
differences in disease outcomes and may help our understanding
of these infections. Importantly, discovery-based studies in-
formed molecular approaches that identified a novel avenue of
immune antagonismutilized by two diverse viral families, provid-
ing a new area for exploration and study. This study highlights the
power and utility of combining systems biology and standard
molecular-based approaches in emerging infectious disease re-
search.
MATERIALS AND METHODS
Cells and viruses. Calu3 cells were utilized as previously described (5–7).
Viral titrations and propagation of SARS-CoV, MERS-CoV, and influ-
enza virus were performed in VeroE6 and MDCK cells using standard
methods. Wild-type (WT) icSARS-CoV was derived from the Baric lab-
oratory’s infectious clone (ic) constructs (53). MERS-CoV (EMC 2012
strain) was kindly provided by Bart L. Haagmans, Erasmus Medical Cen-
ter, Rotterdam, Netherlands, via Material Transfer Agreement. Influenza
A/California/04/2009 (H1N1-09), influenza A/Vietnam/1203/2004
(H5N1-VN1203), and H5N1-VN1203 mutants (NS1trunc124, PB1-
F2del, and PB2-K627E) were derived from a plasmid-based reverse-
genetic system and subsequently amplified in MDCK cells (54). Detailed
information about construction of mutant viruses is included in the sup-
plemental material (see Text S1).
Infections. Experiments using HPAI H5N1, SARS-CoV, or MERS-
CoV were performed in containment laboratories at the University of
Wisconsin-Madison or University of North Carolina-Chapel Hill as pre-
viously described (5, 53). Influenza andCoV infectionswere carried out at
an MOI of 1 (H5N1-VN1203), MOI of 3 (H1N1-09), and MOI of 5
(SARS- and MERS-CoV) as described (5–7).
RNA isolation, microarray processing, and identification of differ-
ential expression. RNA isolation and microarray processing from Calu3
cells were carried out as previously described (5). Differential expression
(DE) was determined by comparing virus-infected replicates to time-
matched mock replicates. Criteria for DE in determining the consensus
ISG list were an absolute log2 FC of1.5 and a false discovery rate (FDR)-
adjusted P value of0.05 for a given time point.
Proteomics reagents, sample preparation, database construction,
and data processing. Proteomics preparation was carried out as previ-
ously described (7). Detailed experimental approaches have been in-
cluded in the supplemental material (see Text S1).
ChIP-PCR. ChIP analysis was performed using the EpiTect ChIP
OneDay kit (Qiagen). Briefly, infected Calu3 cells were cross-linked, har-
vested, and frozen at80°C. Cells were then lysed and chromatin sheared
via sonication to generate chromatin fragments between 250 and
1,000 bp. Sonicated samples were then immunoprecipitated with anti-
STAT1 (clone C-24; Santa Cruz Biotechnology), anti-H3K4me3 (Qia-
gen), anti-H3K27me3 (Qiagen), or anti-mouse IgG (Qiagen) as a control.
To determine the histone modification distribution, quantitative real-
time PCR was performed targeting the 5=UTR (750 bp—TSS [region
750 base pairs upstream of the transcriptional start site]) of select genes;
target and primer information is included in the supplemental material.
ChIP results were reported as fold difference (or differential occupancy),
allowing comparison across multiple samples. For this, each sample was
normalized to the input and then the fold enrichment was calculated
using the CT method. The fold difference for each gene was deter-
mined by dividing the appropriate time-matchedmock by the experimen-
tal group. Finally, the fold difference values were converted to log2 and
plotted. Data presented are the means  standard errors for triplicate
samples.
Meta-analysis of A549 cells infected with H1N1 1918 viruses. RNA
expression data from studies with H1N1 1918 virus infections (33) were
reanalyzed, and ISG expression was examined. Two-channel analysis was
performed using R statistical programming language and bioconductor
package LIMMA. To lower variance, two channel arrays were background
corrected with a zero value and normalized with the Loess method. A
contrastmatrix filewas used to direct which conditions and files should be
used to perform differential expression analysis. LIMMAproduced a gene
list which was carried further for downstream functional analysis.
Accession numbers. Rawmicroarray data have been deposited in the
National Center for Biotechnology Information’s (NCBI) Gene Expres-
sionOmnibus database and are accessible through GEO series GSE33267,
GSE37571, GSE28166, and GSE45042 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi). Raw proteomics data corresponding to peptide iden-
tifications used to populate the AMT tag database are available at the
PRoteomics IDEntification (PRIDE) database (http://www.ebi.ac.uk/
pride/) under the project name “A Systems Biology Approach to Emerg-
ing Respiratory Viral Diseases” in the PRIDE Public Projects folder and
correspond to PRIDE accession numbers 19877 to 19890. The raw quan-
titative proteomics data can be accessed at the Pacific Northwest National
Laboratory’s (PNNL) Biological Mass Spectrometry (MS) Data and Soft-
ware Distribution Center (http://omics.pnl.gov/) in the “Systems Virol-
ogy Contract Data” folder within the “Browse Available Data” folder.
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